Searching…
Dec 10, 2024 · Our study offers new mechanistic insights into ASO-mRNA complexation and underscores the value of pseudoknots in constructing training datasets for machine learning models aimed at designing novel ASO leads.
Alicaforsen is an ASO developed by Atlantic Healthcare that hybridizes with ICAM-1 mRNA and reduces its levels. In clinical trials, treatment with Alicaforsen reduces inflammation and stool frequency, thereby improvin...
Jul 29, 2025 · An ASO’s design is based on its “antisense” complementarity to a specific messenger RNA (mRNA) sequence. When an ASO enters a cell, it binds to its target mRNA through hybridization, forming a double-st...
Apr 18, 2024 · Our study offers new mechanistic insights into ASO-mRNA complexation and underscores the value of pseudoknots in constructing training datasets for machine learning models aimed at designing novel ASO leads.
Dec 9, 2025 · We evaluate variations in ASO hybridization length, position, and chemistry in rabbit reticulocyte lysate (RRL) assays and HEK293T cells. In addition, we explore multiple ASO delivery strategies, includi...
Mar 4, 2025 · ASOs, designed to selectively bind and modulate the expression of specific mRNA sequences, offer a highly targeted approach to gene silencing, splicing modulation, and mRNA degradation.
By binding to the mRNA of the target gene, ASO can inhibit the expression of specific genes, thus showing great potential in the treatment of a variety of diseases, especially hereditary diseases and cancer.
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA).
Jan 5, 2024 · Antisense oligonucleotides (ASOs) are incredibly versatile molecules that can be designed to specifically target and modify RNA transcripts to slow down or halt rare genetic disease...
This article summarizes several of the common mechanisms of antisense gene modulation and more importantly, considerations to take into account when designing an antisense oligonucleotide (ASO).
